A Phase 3 interventional study of Mazdutide and Placebo in Dementia, Mild, Mild Cognitive Impairment and Type 2 Diabetes, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 8 sites in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Dementia with a site in China — 39 open to participants now, 43 under way, 3 of them phase 3. Dementia · China.
Among the 74 studies in Dementia with a site in China, this one is the 10th largest by planned enrollment of the 44 interventional ones that give a count, is one of 8 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 28 of the 42 other live ones, and was the 56th registered.
2,374 studies on the registry are indexed under Dementia; 573 are open to participants now.
Browse Dementia studies →39 of the 74 studies in Dementia with a site in China are open now. Recruiting first, the newest first:
Xinyu ZHANG · Sites in China
Ages 60+
Hong Kong University of Science and Technology · Sites in China
Ages 60–75 · Healthy volunteers
Tianjin Anding Hospital · Sites in China
Ages 55–90
JYAMS PET Research & Development Limited · Sites in China
Ages 50+ · Healthy volunteers
Xuanwu Hospital, Beijing · Sites in China
Ages 50+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 7 · Phase 4 4
First in 2003; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 420 is above the median of 90 across 1,760 interventional studies indexed under Dementia.
Median enrollment 144 across the 44 interventional studies, 2,000 across the 29 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 74 have an industry lead sponsor. The 10 most frequent:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 250 studies on the registry; 147 are open to participants now.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has 2 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
4 of the studies in Dementia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07422857Phase 3JYAMS PET Research & Development LimitedEvaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function | 2026-12-01 |
| NCT07835399Jun XuEfficacy and Safety of Photobiomodulation Therapy in Patients With Mild Cognitive Impairment and Mild Alzheimer's Disease | 2026-12-31 |
| NCT07907042Xinyu ZHANGEffects of Doll Therapy on Apathy and Activities of Daily Living Initiation Deficits in Older Adults With Dementia | 2027-01-30 |
| NCT06978946RenJi HospitalDeep Cervical Lymphaticovenous Anastomosis Surgery for Moderate-to-Advanced Dementia Patients | 2027-02-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 74 studies in Dementia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and early-stage cognitive impairment, defined as mild cognitive impairment (MCI) or mild dementia. Participants are randomized 1:1 to receive once-weekly subcutaneous mazdutide, with dose escalation according to the protocol, or matching placebo, in addition to background glucose-lowering therapy. The primary objective is to determine whether 76 weeks of mazdutide treatment can slow cognitive and functional decline compared with placebo in this population.
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial evaluating the efficacy and safety of mazdutide in 420 participants with T2D and early-stage cognitive impairment (MCI or mild dementia). Participants will be randomized 1:1 to receive once-weekly subcutaneous mazdutide or matching placebo in addition to background glucose-lowering therapy. Mazdutide will be initiated at 2.0 mg once weekly and up-titrated to 4.0 mg, with further escalation to 6.0 mg permitted according to prespecified glycemic, weight, tolerability, and safety criteria. The primary outcome is the between-group difference in change from baseline to Week 76 in the Integrated Alzheimer's Disease Rating Scale (iADRS) score. Secondary outcomes include cognitive and functional measures, structural brain MRI measures, and metabolic outcomes. Exploratory outcomes include blood-based biomarkers, amyloid PET/MRI, CDR-based clinical stage progression, resting-state functional connectivity, and additional cardiometabolic and body-composition measures. Safety and tolerability will be assessed throughout the treatment period.
Participants will generally continue their background glucose-lowering therapy during the trial. If glycemic control remains inadequate after titration to the highest tolerated study dose, additional glucose-lowering therapy may be initiated at the investigator's discretion. Permitted therapies include insulin glargine, metformin, gliclazide sustained-release, and acarbose. Study treatment may be interrupted, dose-reduced, or permanently discontinued for intolerance, adverse events, persistent glycemic instability, or other medical or safety reasons.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Early-stage cognitive impairment (defined as mild cognitive impairment or mild dementia), with all of the following:
Stable glycemic control regimen for ≥3 months prior to screening, meeting one of the following:
Stable treatment regimen for cognitive impairment for at least 3 months prior to screening and commit to its continuation throughout the study period, meeting one of the following criteria:
Exclusion Criteria:
Medical history of:
Severe organ dysfunction, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once-weekly subcutaneous mazdutide, starting at 2.0 mg and titrated to 4.0 mg, with optional escalation to 6.0 mg according to prespecified criteria. Participants unable to tolerate a given dose will remain on the highest tolerated dose, in addition to background glucose-lowering therapy.
Drug: Mazdutide
Participants will receive weekly subcutaneous injections of matched placebo, in addition to their existing glucose-lowering therapy.
Drug: Placebo
Mazdutide is administered once weekly by subcutaneous injection using a prefilled autoinjector pen, preferably on the same day each week. Treatment is initiated at 2.0 mg once weekly and up-titrated to 4.0 mg once weekly during Weeks 4-12 according to individual tolerability. After at least 4 weeks at 4.0 mg, further escalation to 6.0 mg once weekly may be considered if prespecified criteria are met. Participants who are unable to tolerate a given dose may continue treatment at the highest tolerated dose. The total treatment duration is 76 weeks.
Also known as: IBI362
Matching placebo is administered once weekly by subcutaneous injection using a prefilled autoinjector pen. Participants will undergo the same blinded titration and dose-adjustment schedule as the mazdutide group, including corresponding 2.0 mg, 4.0 mg, and, where applicable, 6.0 mg dosing levels. Participants unable to tolerate a given dosing level may remain at the highest tolerated level. The total treatment duration is 76 weeks.
Integrated Alzheimer's Disease Rating Scale (iADRS) Score Change
The change in Integrated Alzheimer's Disease Rating Scale (iADRS) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow cognitive decline. iADRS is a composite endpoint that integrates cognitive and functional assessments (scores from Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) and Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living(ADCS-iADL)) to generate a total score (range: 0-144). The calculation formula is: iADRS score = (85 - ADAS-Cog13 score) + ADCS-iADL score A lower score indicates more severe cognitive and functional impairment.
Time frame: From Baseline to Week 76
Mini-Mental State Examination (MMSE) Score Change
The change in Mini-Mental State Examination (MMSE) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow cognitive decline. It assesses multiple cognitive domains, including orientation, memory, attention and calculation, recall ability, language, and visuospatial skills. The total score ranges from 0 to 30, with higher scores indicating better cognitive function.
Time frame: From Baseline to Week 76
Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score Change
The change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow cognitive decline. The score ranges from 0 to 18, with higher scores indicating greater severity of cognitive and functional impairment.
Time frame: From Baseline to Week 76
Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) Score Change
The change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow cognitive decline. The score ranges from 0 to 85, with higher scores indicating more significant cognitive impairment.
Time frame: From Baseline to Week 76
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Score Change
The change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) scores from baseline to Week 76 will be compared between the treatment group and the placebo group to assess the drug's potential to improve or slow functional decline. The total score ranges from 0 to 59, with lower scores indicating more severe functional impairment.
Time frame: From Baseline to Week 76
Change in Total Brain Volume
The change in total brain volume evaluated by structural MRI from baseline to Week 76 will be compared between the treatment group and the placebo group.
Time frame: From Baseline to Week 76
Change in Total White Matter Lesion Volume
The change in total white matter lesion volume evaluated by sturctural MRI from baseline to Week 76 will be compared between the treatment group and the placebo group.
Time frame: From Baseline to Week 76
Change in hippocampal volume
Change from baseline to Week 76 in hippocampal volume assessed by structural brain MRI.
Time frame: From Baseline to Week 76
Change in entorhinal cortex volume
Change from baseline to Week 76 in entorhinal cortex volume assessed by structural brain MRI.
Time frame: From Baseline to Week 76
Change in Body Weight
Change in body weight from baseline to weeks 76.
Time frame: From Baseline to Week 76.
Change in Body Mass Index (BMI)
Change in BMI from baseline to week 76.
Time frame: From Baseline to Week 76.
Change in Glycated Haemoglobin (HbA1c) Levels
Change in HbA1c levels from baseline to week 76
Time frame: From Baseline to Week 76
Change in Fasting Plasma Glucose Levels
Change in fasting plasma glucose levels from baseline to week 76
Time frame: From Baseline to Week 76
Change in 2-hour Postprandial Plasma Glucose Levels
Change in fasting plasma glucose levels from baseline to week 76
Time frame: From Baseline to Week 76
Incidence of Treatment-emergent Adverse Events
Difference in incidence of treatment-emergent adverse events during the trial period (treatment vs. placebo).
Time frame: From Baseline to Week 76
Incidence of Treatment-emergent Serious Adverse Events
Difference in incidence of serious adverse events during the trial period (treatment vs. placebo).
Time frame: From Baseline to Week 76
Change in Blood-based biomarkers related to AD pathology and neurodegeneration
The change in blood-based biomarkers related to AD pathology and neurodegeneration (includingAmyloid-β (Aβ42/40 ratio), Phosphorylated tau (p-tau217), Glial fibrillary acidic protein (GFAP), and Neurofilament light chain (NfL), etc.)evaluated by Simoa from baseline to Week 76 will be compared between the treatment group and the placebo group.
Time frame: From Baseline to Week 76
Change in brain Aβ burden assessed using [¹⁸F]florbetapir amyloid PET/MRI in participants undergoing this assessment
The change in brain Aβ burden assessed using \[¹⁸F\]florbetapir amyloid PET/MRI in participants undergoing this assessment from baseline to Week 76 will be compared between the treatment group and the placebo group.
Time frame: From Baseline to Week 76
Change in body composition
The change in body composition assessed using dual-energy X-ray absorptiometry from baseline to Week 76 will be compared between the treatment group and the placebo group.
Time frame: From Baseline to Week 76
Change in liver fat and fibrosis
The change in liver fat and fibrosis assessed using transient elastography from baseline to Week 76 will be compared between the treatment group and the placebo group.
Time frame: From Baseline to Week 76
Change in additional cardiometabolic parameters
The change in additional cardiometabolic parameters (including waist circumference, hip circumference, waist-to-hip ratio, blood pressure, lipid profile, pancreatic β-cell function, and insulin resistance) from baseline to Week 76 will be compared between the treatment group and the placebo group.
Time frame: From Baseline to Week 76
Changes in regional structural brain MRI measures
Changes from baseline to Week 76 in exploratory regional structural MRI measures, including total grey and white matter volumes, lobar grey matter volumes, volumes of subcortical grey matter structures, and volumes and cortical thickness of other prespecified neurodegeneration-sensitive regions.
Time frame: From Baseline to Week 76
Plan to share: Yes — Availability: De-identified participant data may be timely shared with qualified researchers upon request, subject to review and approval. Access Conditions: Data requests require a valid research proposal and signed data use agreement. Approval is contingent on compliance with applicable laws and ethical guidelines. Timing: Data will become available after study completion and primary publication for 3 years. Restrictions: Certain data types may be excluded due to privacy or regulatory requirements. Contact: Requests should be submitted to the study sponsor for consideration.
Supporting information: Study protocol, Informed consent form
Time frame: Data will become available after study completion and primary publication for 3 years.
Access criteria: Data requests require a valid research proposal and signed data use agreement. Approval is contingent on compliance with applicable laws and ethical guidelines.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Aug 2029, 46 months after the start.
Of 34 phase 3 interventional studies under Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 46 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mazdutide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School →